Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation
Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai
Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance
In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance positioned
Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")
In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)/the
